

1

2

## Lung Perfusion Disturbances Detected with MRI

3

### in Non-Hospitalized Post-COVID-19 Individuals with Dyspnea 3 -13 Months after

4

### the Acute Disease

5

6

7 Jimmy Yu,<sup>1,2</sup> Tobias Granberg,<sup>3,4</sup> Roya Shams,<sup>3</sup> Sven Petersson,<sup>4,5</sup> Magnus Sköld,<sup>6, 7</sup>  
8 Sven Nyrén,<sup>1,2</sup> Johan Lundberg,<sup>3,4</sup>

9

1. Department of Radiology Solna, Karolinska University Hospital, Stockholm, Sweden.

10

2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

11

3. Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.

12

4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

13

5. Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University  
14 Hospital, Stockholm, Sweden.

15

6. Department of Respiratory Medicine and Allergy, Karolinska University Hospital,  
16 Stockholm, Sweden.

17

7. Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

18

#### Corresponding author

19

Johan Lundberg

20

Department of Neuroradiology, B5:19

21

Karolinska University Hospital

22

Eugeniavägen 3

23

171 76, Stockholm, Sweden

24

j.lundberg@ki.se

25

Phone (cell): +46 72 580 29 49

26

27

#### Keywords

28

MeSH terms: COVID-19, Biomarkers, Dyspnea, Magnetic Resonance Imaging, Perfusion

## 29 **Abstract**

### 30 *Background*

31 Dyspnea is a prevalent symptom in the post-COVID-19 condition, though its mechanisms are  
32 largely unknown. Lung perfusion abnormalities have been reported in acute COVID-19 and could  
33 be suspected in patients with lingering dyspnea after the acute phase.

### 34 *Objectives*

35 To detect pulmonary perfusion disturbances in non-hospitalized post-COVID condition with  
36 persistent dyspnea 4-13 months after the disease onset.

### 37 *Methods*

38 Non-hospitalized individuals reporting persistent dyspnea after COVID-19 and matched healthy  
39 controls were prospectively recruited between October 2020 and May 2021 to undergo pulmonary  
40 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), six-minute walk test, and  
41 self-reported scales questionnaires on dyspnea and physical activity. The DCE-MRI perfusion  
42 images were quantified into two parametric values: mean time-to-peak (TTP) and TTP ratio.

### 43 *Results*

44 Twenty-eight persons with post-COVID condition and persistent dyspnea (mean age  $46.5 \pm 8.0$   
45 years, 75% women) and 22 healthy controls (mean age  $44.1 \pm 10.8$  years, 73% women) were  
46 included. The post-COVID group had higher mean pulmonary TTP ( $0.43 \pm 0.04$  vs.  $0.41 \pm 0.03$ ,  
47  $P=0.011$ ) and higher TTP ratio ( $0.096 \pm 0.052$  vs.  $0.068 \pm 0.027$ ,  $P=0.032$ ). Notably, post-COVID  
48 males had the highest values (mean TTP  $0.47 \pm 0.02$ , TTP ratio  $0.160 \pm 0.039$ ,  $P<0.001$  for both  
49 values compared to male controls and post-COVID females). Correlation between dyspnea and  
50 perfusion parameters was demonstrated in the males ( $r=0.83$ ,  $P<0.001$  for mean TTP;  $r=0.76$ ,  
51  $P=0.003$  for TTP ratio), but not in females.

### 52 *Conclusions*

53 Lung perfusion disturbances were detected in males reporting post-COVID dyspnea using  
54 perfusion parameters from DCE-MRI. The distinct sex difference has implications for  
55 understanding the perplexing post-COVID pathophysiology and warrants future studies. DCE-MRI  
56 could provide biomarkers for such studies.

57

## 58 Introduction

59 Post-COVID-19 condition, also known as “long-COVID”, or post-acute COVID-19 syndrome  
60 (PACS), is prevalent and can persist for months after the acute illness [1]. One prominent symptom  
61 is dyspnea, found in 24.5 % of hospitalized patients and 39.9 % in non-hospitalized patients 60  
62 days after onset of infection [2]. In hospitalized patients, potential explanations include fibrotic-like  
63 changes visualized by computed tomography (CT), reduced spirometry volumes, and diffusion  
64 capacity [3–6]. However, a sizeable group of non-hospitalized patients also have a high incidence  
65 of dyspnea, with scarce objective findings on CT and lung function tests, but the non-hospitalized  
66 patient group is not well studied [7]. In these patients, the pathophysiological mechanisms are less  
67 clear.

68 During the acute SARS-CoV-2 infection, the lungs are the primary site of infection, developing  
69 into, in the worst case, an ARDS pattern [8–10]. Pulmonary involvement leads to local tissue  
70 disruption, including microvascular damage. Clinical reports support similar findings regarding an  
71 association between pulmonary hypertension and more severe disease [11]. Radiological  
72 methods including contrast-enhanced CT, dual-energy CT (DECT), and single-photon emission  
73 computed tomography combined with CT (SPECT-CT) indicate disturbances in pulmonary blood  
74 distribution [12–17]. The combined impression of unequal blood distribution in single time point  
75 scans (DECT) or composite tracer distribution (SPECT) has further support from findings in a case  
76 report of an ICU patient using dynamic contrast-enhanced magnetic resonance imaging (DCE-  
77 MRI) [18]. It has been speculated that lung perfusion disturbances could partly explain the clinical  
78 deteriorations in the acute phase [19]. The importance of examining lung perfusion in post-COVID  
79 patients has been stressed in one exploratory SPECT-CT study [20]. Indeed, early SPECT-CT  
80 studies in non-hospitalized post-COVID patients have suggested residual perfusion disturbances  
81 [21].

82 Lung perfusion can be studied using pulmonary angiography, DECT, SPECT/CT, and DCE-MRI.  
83 The essential advantage that sets DCE-MRI apart from the former methods is the ability to render  
84 both spatial and temporal information with a reasonable resolution, enabling detection of subtle  
85 perfusion impairments and possibly shunts. DCE-MRI is a clinically applied method for brain  
86 perfusion imaging and has also been successfully applied in lung diseases such as chronic  
87 obstructive pulmonary disease, cystic fibrosis, pulmonary embolism, pulmonary artery stenosis,  
88 and pulmonary vasculitis [22,23]. In addition, the ability to process DCE-MRI parametric maps into  
89 a few summarizing numeric values facilitates comparisons between different individuals and time

90 points. The lack of ionizing radiation is advantageous too, especially for repeated examinations in  
91 young persons.

92 We hypothesized that lung perfusion disturbances might exist within this patient group and  
93 contribute to dyspnea. Therefore, in this prospective study, we applied DCE-MRI to investigate if  
94 pulmonary perfusion disturbance exists in non-hospitalized post-COVID individuals and whether  
95 it might be associated with dyspnea.

## 96 **Methods**

### 97 *Ethical considerations*

98 The Regional Ethics Review Board in Stockholm and the Swedish Ethical Review Authority  
99 approved this prospective cross-sectional study performed October 2020 and May 2021 (original  
100 approval number 2018/2416-31 with amendments 2020-00047, 2020-02535, 2021-00815).  
101 Written informed consent was obtained from all participants.

### 102 *Participant selection and enrollment*

103 Inclusion criteria for the post-COVID condition group was a history of past COVID-19 infection,  
104 verified by real-time polymerase chain reaction (rt-PCR) and persistent dyspnea at enrollment.  
105 Participants were recruited through a patient network in Sweden and kindly asked to recruit an  
106 age and sex-matched healthy control, if possible. Controls were included if they had a negative  
107 antibody test within three weeks from the imaging point and the absence of COVID-suspect  
108 symptoms since the pandemic started.

109 Exclusion criteria for both groups were (i) a history of smoking for more than five years, (ii) any  
110 cardiovascular or (iii) pulmonary conditions requiring medical follow-up or treatment. In addition,  
111 all participants were asked to fill out an MRI safety checklist, and any contraindications meant  
112 exclusion from the study.

113 One male person with idiopathic pulmonary fibrosis [24], diagnosed by the Respiratory medicine  
114 clinic at Karolinska University Hospital, was additionally included as a positive control. He was in  
115 his 80s (more than 4 SD older than the post-COVID group) but with a BMI of 23,8 (within 1 SD).  
116 His disease severity was assessed as “mild to moderate” [25] based on a forced vital capacity of  
117 92 %, predicted and diffusion capacity of 63 %, and did not require long-term oxygen treatment.  
118 Computed tomography showed subpleural reticular changes with traction bronchiectasis and no

119   honeycombing. The total volume of morphologic changes was visually assessed to be 10-20% of  
120   the total lung volume.

#### 121   *Clinical data acquisition*

122   All clinical data were collected directly in conjunction with the MRI imaging session. Essential  
123   patient characteristics were recorded: age, sex, body height, and body weight from which the body  
124   mass index (BMI) was calculated, date of disease onset, and confirmed rt-PCR test result.

125   Dyspnea severity was quantified through two validated self-reported symptom scales: the modified  
126   Medical Research Council dyspnea scale (mMRC) and Chronic Obstructive Pulmonary Disease  
127   assessment test (CAT) [26,27]. The CAT scale includes several questions regarding different  
128   symptoms related to COPD. Only one question, the one related to exertional dyspnea, was used  
129   in the analysis. In both scales, a higher number means more dyspnea.

130   Subjective exertional impairment was quantified through the validated self-reported Frändin-  
131   Grimby [28]. A lower number means less daily physical activity.

132   Objective exertional impairment was quantified through a 6-min walking test (6MWT), performed  
133   according to the American Thoracic Society 2002 guidelines by J.Y. (pulmonologist and fifth-year  
134   radiology resident) [29]. We also related the absolute walking distance to expected values based  
135   on normative data [30] to account for differences in age, body height, and body weight which might  
136   affect the absolute walking distance.

#### 137   *MRI image acquisition*

138   Pulmonary imaging was performed by J.Y. and R.S. (MRI technologist) under the supervision of  
139   T.G. (radiologist) on a Siemens MAGNETOM Skyra 3 Tesla MRI scanner (Siemens Healthineers,  
140   Erlangen, Germany). The imaging protocol was designed by J.Y., T.G., S.P. (MRI physicist), and  
141   J.L. (radiologist), including three morphological sequences and one perfusion sequence. Prior to  
142   entering the scanner, the patient was given breath-hold training. The entire imaging session lasted  
143   15-20 minutes.

144   Three morphological image non-enhanced sequences, each performed during inspiration breath-  
145   hold for 16 seconds, were used to identify lung opacifications: a coronal 2D T2-weighted half-  
146   Fourier single-shot spin-echo ("HASTE", field-of-view 400×400 mm, voxel size 2.1 × 2.1 × 5 mm,  
147   echo/repetition times at 23/400 ms, 36 slices); a transverse 2D T1-weighted spoiled gradient echo  
148   ("VIBE", field-of-view 262×400 mm, voxel size 1.0 × 1.0 × 4 mm, flip angle 5 °, echo/repetition

149 times at 1.9/4 ms, 72 slices); a coronal 3D ultrashort echo-time spiral VIBE (field-of-view 600×600  
150 mm, voxel size 2.3 × 2.3 × 2.3 mm, flip angle 5 °, echo/repetition times at 0.05/2.62 ms, 104 slices).

151 The DCE-MRI was acquired through a 4D time-resolved MRI angiography sequence with a  
152 keyhole T1-weighted gradient-recalled-echo (“TWIST”, field-of-view 450 × 450 mm, voxel size 1.5  
153 × 1.5 × 4 mm, echo/repetition times at 0.64/1.9 ms, 26 slices, a total of 90 phases in 40 seconds).  
154 A Spectris Solaris EP contrast injector (MEDRAD, Pittsburgh, USA; Bayer, Leverkusen, Germany)  
155 was used to administer gadoterate contrast agent (Clariscan, GE Healthcare, Chicago, USA), 0.5  
156 mmol/ml, 2 ml, followed by 20 ml 0.9% saline solution with five ml/s. The patients were told to  
157 inhale and hold their breath for as long as possible during the 40-second image acquisition,  
158 preceded by ten deep breaths.

159 Repeatability was evaluated by performing DCE-MRI twice on two consecutive days in one healthy  
160 control.

#### 161 *MRI image assessment and quantification*

162 Morphological imaging was evaluated by J.Y. and independently verified by J.L. or S.N.  
163 (radiologists). MRI perfusion series were analyzed using MATLAB (version R2020b, The  
164 Mathworks Inc., Natick, USA) as previously described using an in-house developed post-  
165 processing pipeline [18]. Briefly, lungs were manually masked, and regions of interest (ROI) were  
166 manually selected in the pulmonary artery (PA) before its bifurcation and in the aortic arch at its  
167 superior portion. This was performed by J.Y. and independently verified by J.L., blinded to clinical  
168 data. To allow for a structured and quantitative comparison between individuals and groups, the  
169 perfusion scans were normalized in the time domain to the peaks of the PA (as 0) and aorta (as  
170 1) and summarized using two numeric parameters: Time-to-peak (TTP) ratio and mean TTP. TTP  
171 parametric maps were calculated using the MATLAB function `max`. Temporal smoothing with a  
172 robust Locally Weighted Scatterplot Smoothing algorithm was applied before TTP calculation.  
173 Mean TTP was calculated as the mean of lung TTP values between PA and aorta. TTP ratio was  
174 calculated as the fraction of voxels with TTP values later than the aorta, i.e., a bolus arrival after  
175 the aorta.

#### 176 *Statistics analysis*

177 All values reported are the mean and standard deviations unless explicitly stated otherwise.  
178 Categorical variables were evaluated with the Pearson chi-square test, and continuous variables  
179 were assessed with the Students t-test, while ordinal variables were evaluated with the Mann-

180 Whitney test. When analyzing sex differences, ANOVA with Dunn-Sidak corrections for multiple  
181 comparisons was used since there is an uneven number of individuals to compare between  
182 multiple groups. Finally, correlations were assessed with the Spearman correlation method.  
183 Statistical analyses were performed using MATLAB (version R2020b, The Mathworks Inc., Natick,  
184 USA). To generate Figures 3 and 4, curves were smoothed using the moving mean method with  
185 a smoothing factor of 0.2, then interpolated using the modified Akima method. This was done to  
186 generate a unified x-axis for simultaneous plotting. No interpolation was performed prior to  
187 calculating the mean TTP and TTP ratio. Normalized TTP-distribution curves from the two MRI  
188 scans performed in one healthy control were compared, with the difference between these two  
189 curves expressed as the mean coefficient of variation.

## 190 **Results**

191 In total, 51 participants were recruited. Included in the data analysis were 28 individuals with  
192 longstanding symptoms and RT-qPCR positive testing at the time of disease, 22 healthy controls,  
193 and 1 positive control with idiopathic pulmonary fibrosis. For brevity, the RT-qPCR positive group  
194 with longstanding symptoms following COVID-19 will be referred to as the post-COVID group. In  
195 addition, 1 patient with idiopathic pulmonary fibrosis was included as a positive control. None in  
196 the post-COVID group had a history of being hospitalized or receiving treatment during the acute  
197 phase. All participants tolerated the image session well. A flow chart of the study inclusions is  
198 presented in Figure 1. The two cohorts had no significant difference in neither mean age, the  
199 proportion of female participants, mean weight, nor mean BMI, as detailed in Table 1. In the post-  
200 COVID group, the mean time from symptom onset to the exam was  $7.7 \pm 3.6$  months, with a  
201 biphasic distribution. About one-half of the post-COVID group performed imaging 4-6 months after  
202 symptom debut, and the rest 10-13 months after, reflecting the first and second wave of COVID-  
203 19 pandemic in Sweden.

204 The post-COVID group had a lower current self-reported physical activity ( $2.5 \pm 1$ ) than the control  
205 group ( $4 \pm 2$ ,  $P < 0.001$ ) according to Frändin-Grimby, but the re-called physical activity ( $5 \pm 1$ ) before  
206 COVID-19 was not significantly different ( $P = 0.29$ ) from the controls. The post-COVID group also  
207 reported more dyspnea on CAT ( $4 \pm 1$  vs.  $1 \pm 2$ ,  $P < 0.001$ ) and mMRC ( $2 \pm 2$  vs.  $1 \pm 1$ ,  $P < 0.001$ ).

208 When performing 6MWT, the post-COVID group had a shorter walking distance, both in actual  
209 meters ( $583 \pm 111$  vs.  $677 \pm 77$ ,  $P = 0.001$ ) and normalized value, as a percentage of the expected  
210 reference value ( $102.0 \pm 17.7$  % vs.  $117.0 \pm 12.5$  %,  $P = 0.002$ ). However, both groups remained  
211 within the clinically normal range.



212 No systematic structural changes were identified on the morphological lung MRI imaging. Only  
213 small atelectatic opacities (max. 7 mm) in 4/28 (14%) participants in the post-COVID group were  
214 visualized. None of the controls had any detectable lung changes. There was no correlation  
215 between time from symptom onset to MRI and any of the perfusion parameters.

216 On the TTP-maps, there was visually a late bolus arrival in many post-COVID participants,  
217 exemplified in Figure 2. The TTP ratio, capturing bolus arrival later than the aortic peak in the lung  
218 parenchyma, was significantly higher in the post-COVID group at  $0.096 \pm 0.052$  vs.  $0.068 \pm 0.027$  in  
219 the control group ( $P=0.032$ ). The mean TTP was significantly higher in the post-COVID group at  
220  $0.43 \pm 0.04$  vs.  $0.41 \pm 0.03$  ( $P=0.011$ ). A higher mean TTP indicates an overall slower inflow of  
221 contrast bolus. Notably, the post-COVID group displayed a more considerable within-group  
222 variability regarding both TTP ratio and mean TTP (Figure 3). The group differences are also  
223 reported in Table 1.

224 Sub-group analyses of a possible sex difference revealed that post-COVID males had worse mean  
225 TTP ( $0.47 \pm 0.03$  vs.  $0.40 \pm 0.03$ ,  $P=0.001$ ) and TTP ratio ( $0.160 \pm 0.039$  vs.  $0.082 \pm 0.027$ ,  $P=0.001$ )  
226 compared to the male control group. The comparisons are summarized in Figure 4. The female  
227 post-COVID group did not differ significantly from the female control group, neither regarding  
228 mean TTP nor TTP ratio. Notably, the female post-COVID participants displayed greater variability  
229 in perfusion metrics relative to the female controls (Figure 4).

230 The overall correlation between self-reported dyspnea, 6MWT and TTP values are visualized as  
231 scatterplots (Figure 5). Analyzing all participants, we found a correlation between CAT and mean  
232 TTP ( $r = 0.35$ ,  $P=0.013$ ). For males, this correlation was even more pronounced, both between  
233 CAT and mean TTP ( $r = 0.83$ ,  $P=< 0.001$ ), and between CAT and TTP ratio ( $r = 0.76$ ,  $P=0.003$ ).  
234 Results from 6MWT did not correlate to MRI-DCE parameters.

235 To put the degree of perfusion impairment of the post-COVID group into a clinical perspective,  
236 one male patient in his 80s with idiopathic pulmonary fibrosis was included in the study as a  
237 positive control. The walking distance was 440 m (87% of the expected reference value). The  
238 TTP-mean for this patient was 0.45 and the TTP-ratio 0.15, which is comparable to the most  
239 pathological values seen in the post-COVID group. This patient also had subtle peripheral  
240 morphologic changes involving a larger lung volume compared to the worst post-COVID  
241 participants.



242 One healthy control performed DCE-MRI on two consecutive days to further characterize the DCE  
243 sequence and post-processing variability. The mean TTP was 0.39 and 0.38, TTP-ratio was  
244 0.0248 and 0.0238, respectively, over the two sessions (Figure 6).

245 Diaphragm movement during the DCE sequence was evaluated for all participants as a possible  
246 source of variability. The reference point for the movement was the topmost point of the right  
247 diaphragm in the mid-coronal slice (slice 13 of 26). The movement was quantified in the number  
248 of voxels during the bolus transit. Six participants had a diaphragm movement exceeding two  
249 voxels (3 mm), and the most considerable movement during bolus passage was six voxels (9  
250 mm). Most (86%) of the participants could hold their breath during the entire 40 seconds image  
251 acquisition. Seven subjects (14%) resumed breathing in the latter half, well after bolus transit.

## 252 **Discussion**

253 The high prevalence of post-COVID dyspnea is developing into a potentially sizeable clinical and  
254 socioeconomic issue. However, in non-hospitalized patients, objective findings are scarce, and  
255 the mechanisms are largely unknown. Lung perfusion disturbances are a significant  
256 pathophysiologic finding in acute COVID-19 infection. We, therefore, wanted to investigate if  
257 perfusion disturbances persist in post-COVID. Applying DCE-MRI, we detected lung perfusion  
258 disturbances in a prospective convenience sample of non-hospitalized post-COVID patients. In  
259 males, there was a significant correlation with dyspnea.

260 Sex differences in pathophysiology have been reported regarding acute COVID-infection. Men  
261 have a higher expression of angiotensin-converting enzyme II-receptor, abundant in the lung, and  
262 a higher propensity for COVID-associated respiratory failure and mortality [31]. The post-COVID  
263 perfusion sex difference could thus be anticipated. Notably, in our study, post-COVID males had  
264 distinctively worse perfusion parameters than healthy male controls and female counterparts. The  
265 lack of a stronger correlation between perfusion and clinical parameters in females could partly  
266 be expected, given that perfusion abnormalities were less pronounced among females. We should  
267 point out that our results do not exclude the possibility of lung perfusion disturbances in females.  
268 We observed considerable variability in the female group, with some individuals showing impaired  
269 perfusion comparable to the males. One possible explanation is that, in our convenience sample,  
270 we have recruited a more heterogeneous female population with other underlying causes for their  
271 self-reported dyspnea.

272 An essential factor to discuss is that the imaging was conducted during rest and not exertion.  
273 Pulmonary perfusion is directly linked to cardiac output, which can increase many-fold during  
274 heavy physical exertion. In addition, the lung perfusion becomes more heterogeneous as  
275 pulmonary blood flow increases [32]. This increase might be more pronounced in post-COVID  
276 individuals. Due to practical reasons, it is challenging to perform DCE-MRI during physical  
277 exertion, which applies to other perfusion imaging methods as well. A possible extension of the  
278 current work could be pharmacologically induced stress-testing during DCE-MRI, thereby  
279 highlighting possible group differences.

280 Based on our results, we believe this lung DCE-MRI method is feasible for exploring lung perfusion  
281 in a larger clinical setting, applicable to any MRI scanner. When done in conjunction with other  
282 diagnostic and interventional trials, the underlying cause of perfusion disturbances may be further  
283 elucidated, be it microthrombi, parenchymal destruction, dysregulation, or secondary to ventilation  
284 disturbances. DCE-MRI was chosen as our study method for its many advantages, including  
285 temporal information and lack of radiation. Its application in lung perfusion imaging in other  
286 conditions has thus far yielded convincing results [23]. Analysis of TTP parametric maps in high-  
287 altitude pulmonary edema susceptible individuals have previously been reported [33]. The post-  
288 processing method whereby the TTP maps are normalized in the time domain and summarized  
289 into mean TTP and TTP ratio is straightforward and has been successfully applied in one patient  
290 treated with intensive care for COVID-19 and a porcine model simulating severe COVID-19 [18].

291 To our knowledge, this is the largest cohort examined using lung DCE-MRI in COVID-19 and post-  
292 COVID. These patients did, by definition, not receive any medical treatment during their acute  
293 phase, possibly representing a “mild” stratum of patients. Our findings thus indicate a possible  
294 physiological disturbance beyond morphological changes, similar to other studies using DECT or  
295 hyperpolarized  $^{129}\text{Xe}$  MRI [6,34]. What is surprising is our finding of perfusion disturbances up to  
296 one year after symptom onset. This finding could suggest a long-lasting or even perpetual lung  
297 injury in some patients. Further studies would elucidate the factors predicting long-term outcomes.

298 This study has some limitations, including a lack of other supporting imaging modalities. CT scans  
299 would likely detect morphological lung changes with higher sensitivity, but the current MRI protocol  
300 was optimized with advanced morphological imaging, including ultra-short echo time imaging that  
301 has recently been successfully applied in cystic fibrosis [35]. This study can be regarded as  
302 exploratory on the potential use of DCE-MRI in post-COVID, and future studies should combine  
303 multiple imaging modalities such as CT, echocardiography, and pulmonary physiological

304 measurements such as spirometry. Nevertheless, we detect heterogeneity in our post-COVID  
305 group, indicative of a significant systematic difference on the group level. The heterogeneity  
306 supports a possible perfusion problem in the post-COVID group. A technical limitation that is hard  
307 to mitigate is the possible contribution of inspiration during breath-hold. A higher degree of  
308 inspiration can increase pulmonary resistance by stretching alveolar capillaries and by vessel  
309 compression due to higher intrathoracic pressure [36]. Nevertheless, the repeatability of a healthy  
310 volunteer was excellent. In addition, the unstructured recruitment of patients through a network of  
311 self-identified “long haulers” following COVID-19 could be considered both a weakness and a  
312 strength. The potentially increased heterogeneity is offset by a better reflection of clinical reality.  
313 In hindsight, with regards to perfusion disturbances detected predominantly in men, the male  
314 participants would have been more numerous. It could be argued that the clinical tests we used,  
315 originally meant for debilitating lung diseases, were not an optimal match for our participants. In  
316 addition, *post hoc* assessments of physical activity before COVID-19 may also be subject to a  
317 recall bias. Nevertheless, our results suggest that perfusion impairment contributes to dyspnea  
318 and reduced exercise capacity in our sample of non-hospitalized post-COVID individuals.

319 In conclusion, by calculating the mean TTP and TTP ratio from DCE-MRI, perfusion disturbances  
320 can be detected in non-hospitalized patients long after an acute COVID-19 infection. This method  
321 could investigate other patient groups, the most salient being hospitalized, post-COVID patients.  
322 Our results regarding sex differences are important to consider for future studies addressing the  
323 role of lung perfusion disturbances in post-COVID pathophysiology.

#### 324 **Acknowledgments**

325 The authors are grateful to the study participants for providing their time.

#### 326 **Funding information**

327 This study was supported by grants from the Swedish Heart and Lung Foundation (No 20210114)  
328 and Karolinska Institutet. JL was supported by MedTechLabs and a private donation by Tedde  
329 Jeansson Sr.

#### 330 **Conflict of interest statement**

331 The authors declare no conflict of interest.

#### 332 **Data availability statement**

333 The anonymized datasets generated and analyzed in the study are available from the  
334 corresponding author on reasonable request.

### 335 **References**

336 1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WCCDWG on P-C-19. A clinical  
337 case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* 2021.

338 2. Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, *et al.* Prevalence of post-  
339 COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic  
340 review and meta-analysis. *Eur J Intern Med* 2021; 92: 55–70.

341 3. Huang C, Huang L, Wang Y, *et al.* 6-month consequences of COVID-19 in patients discharged  
342 from hospital: a cohort study. *Lancet* 2021; 397: 220–32.

343 4. Han X, Fan Y, Alwalid O, *et al.* Six-Month Follow-up Chest CT findings after Severe COVID-19  
344 Pneumonia. *Radiology* 2021; 299: 203153.

345 5. Li H, Zhao X, Wang Y, *et al.* Damaged lung gas exchange function of discharged COVID-19  
346 patients detected by hyperpolarized <sup>129</sup>Xe MRI. *Sci Adv* 2021; 7: eabc8180.

347 6. Grist JT, Chen M, Collier GJ, *et al.* Hyperpolarized <sup>129</sup>Xe MRI Abnormalities in Dyspneic  
348 Participants 3 Months after COVID-19 Pneumonia: Preliminary Results. *Radiology* 2021: 210033.

349 7. Sudre CH, Murray B, Varsavsky T, *et al.* Attributes and predictors of long COVID. *Nat Med*  
350 2021; 27: 626–31.

351 8. Ackermann M, Verleden SE, Kuehnel M, *et al.* Pulmonary Vascular Endothelialitis, Thrombosis,  
352 and Angiogenesis in Covid-19. *New Engl J Med* 2020; 383: 120–8.

353 9. Bösmüller H, Traxler S, Bitzer M, *et al.* The evolution of pulmonary pathology in fatal COVID-  
354 19 disease: an autopsy study with clinical correlation. *Virchows Arch* 2020; 477: 349–57.

355 10. Polak SB, Gool ICV, Cohen D, Thüsen JH von der, Paassen J van. A systematic review of  
356 pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of  
357 disease progression. *Modern Pathol* 2020; 33: 2128–38.

358 11. Pagnesi M, Baldetti L, Beneduce A, *et al.* Pulmonary hypertension and right ventricular  
359 involvement in hospitalised patients with COVID-19. *Heart* 2020; 106: 1324–31.

- 360 12. Si-Mohamed S, Chebib N, Sigovan M, *et al.* In vivo demonstration of pulmonary microvascular  
361 involvement in COVID-19 using dual-energy computed tomography. *European Respir J* 2020; 56:  
362 2002608.
- 363 13. Ridge CA, Desai SR, Jeyin N, *et al.* Dual-Energy CT Pulmonary Angiography (DECTPA)  
364 Quantifies Vasculopathy in Severe COVID-19 Pneumonia. *Radiology Cardiothorac Imaging* 2020;  
365 2: e200428.
- 366 14. Santamarina MG, Riscal DB, Beddings I, *et al.* COVID-19: What Iodine Maps From Perfusion  
367 CT can reveal—A Prospective Cohort Study. *Crit Care* 2020; 24: 619.
- 368 15. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated  
369 with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. *Radiology* 2020; 296:  
370 201544.
- 371 16. Jain A, Doyle DJ, Mangal R, *et al.* “Mosaic Perfusion Pattern” on Dual-Energy CT in COVID-  
372 19 Pneumonia: Pulmonary Vasoplegia or Vasoconstriction? *Radiology Cardiothorac Imaging*  
373 2020; 2: e200433.
- 374 17. Evbuomwan O, Engelbrecht G, Bergman MV, Mokwena S, Ayeni OA. Lung perfusion findings  
375 on perfusion SPECT/CT imaging in non-hospitalized de-isolated patients diagnosed with mild  
376 COVID-19 infection. *Egypt J Radiology Nucl Medicine* 2021; 52: 144.
- 377 18. Rysz S, Al-Saadi J, Sjöström A, *et al.* COVID-19 pathophysiology may be driven by an  
378 imbalance in the renin-angiotensin-aldosterone system. *Nat Commun* 2021; 12: 2417.
- 379 19. Lucatelli P, Monte MD, Rubeis GD, *et al.* Did we turn a blind eye? The answer is simply there.  
380 Peripheral pulmonary vascular thrombosis in COVID-19 patients explains sudden worsening of  
381 clinical conditions. *Imaging* 2020; 12: 4–7.
- 382 20. Dhawan RT, Gopalan D, Howard L, *et al.* Beyond the clot: perfusion imaging of the pulmonary  
383 vasculature after COVID-19. *Lancet Respir Medicine* 2020; 9: 107–16.
- 384 21. Buonsenso D, Giuda DD, Sigfrid L, *et al.* Evidence of lung perfusion defects and ongoing  
385 inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. *Lancet Child*  
386 *Adolesc Heal* 2021; 5: 677–80.

- 387 22. Risse F, Eichinger M, Kauczor HU, Semmler W, Puderbach M. Improved visualization of  
388 delayed perfusion in lung MRI. *Eur Radiol* 2011; 77: 105–10.
- 389 23. Schiwiek M, Triphan SMF, Biederer J, *et al.* Quantification of pulmonary perfusion  
390 abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function.  
391 *Eur Radiol* 2021: 1–12.
- 392 24. Raghu G, Remy-Jardin M, Myers JL, *et al.* Diagnosis of Idiopathic Pulmonary Fibrosis. An  
393 Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Resp Crit Care* 2018; 198: e44–68.
- 394 25. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future.  
395 *European Respir Rev* 2014; 23: 220–4.
- 396 26. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the  
397 Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with  
398 chronic obstructive pulmonary disease. *Thorax* 1999; 54: 581.
- 399 27. Daynes E, Gerlis C, Briggs-Price S, Jones P, Singh SJ. COPD assessment test for the  
400 evaluation of COVID-19 symptoms. *Thorax* 2020; 76: thoraxjnl-2020-215916.
- 401 28. Grimby G, Frändin K. On the use of a six-level scale for physical activity. *Scand J Med Sci*  
402 *Spor* 2018; 28: 819–25.
- 403 29. Anon. ATS Statement. *Am J Resp Crit Care* 2012; 166: 111–7.
- 404 30. Chetta A, Zanini A, Pisi G, *et al.* Reference values for the 6-min walk test in healthy subjects  
405 20–50 years old. *Resp Med* 2006; 100: 1573–8.
- 406 31. Haitao T, Vermunt J, Abeykoon J, *et al.* COVID-19 and Sex Differences: Mechanisms and  
407 Biomarkers. *Mayo Clin Proc* 2020; 95: 2189–203.
- 408 32. Burnham KJ, Arai TJ, Dubowitz DJ, *et al.* Pulmonary perfusion heterogeneity is increased by  
409 sustained, heavy exercise in humans. *J Appl Physiol* 2009; 107: 1559–68.
- 410 33. Dehnert C, Risse F, Ley S, *et al.* Magnetic Resonance Imaging of Uneven Pulmonary  
411 Perfusion in Hypoxia in Humans. *Am J Resp Crit Care* 2006; 174: 1132–8.

412 34. Santamarina MG, Boisier D, Contreras R, Baque M, Volpacchio M, Beddings I. COVID-19: a  
413 hypothesis regarding the ventilation-perfusion mismatch. *Crit Care* 2020; 24: 395.

414 35. Heidenreich JF, Weng AM, Metz C, *et al.* Three-dimensional Ultrashort Echo Time MRI for  
415 Functional Lung Imaging in Cystic Fibrosis. *Radiology* 2020; 296: 191–9.

416 36. Simmons DH, Linde LM, Miller JH, O'Reilly RJ. Relation between lung volume and pulmonary  
417 vascular resistance. *Circ* 1961; 9: 465–71.

418

419




420 **Table 1:** Patient characteristics, clinical parameters and perfusion results.

Parameter	Patients (n = 28)	Controls (n = 22)	Patient vs. - Controls difference	P value
Age, mean $\pm$ SD (years)	46.5 $\pm$ 8	44.1 $\pm$ 10.8	2.4 (5.5%)	0.37
Females, n (%)	21 (75)	16 (73)		
Weight, mean $\pm$ SD (kg)	75.3 $\pm$ 13.5	73.8 $\pm$ 12.1	1.5 (2.0%)	0.68
BMI, mean $\pm$ SD	26 $\pm$ 5.1	25 $\pm$ 3.4	1.0 (4.1%)	0.42
<b>Self-assessment scales</b>				
Frändin-Grimby (before/after COVID-19 for patients), median $\pm$ IQR	5 $\pm$ 2 / 2.5 $\pm$ 1	4 $\pm$ 2		0.29 / <0.001
CAT dyspnea rating, median $\pm$ IQR	4 $\pm$ 1	1 $\pm$ 2		<0.001
mMRC dyspnea rating, median $\pm$ IQR	2 $\pm$ 2	1 $\pm$ 1		<0.001
<b>Walking test</b>				
6MWT, mean $\pm$ SD (m)	583 $\pm$ 111	677 $\pm$ 77	-94 (-14%)	
Normalized 6MWT, mean $\pm$ SD (%)	102.0 $\pm$ 17.7	117.0 $\pm$ 12.5	-15 (-13%)	0.002
<b>Perfusion parameters</b>				
Mean TTP, mean $\pm$ SD	0.41 $\pm$ 0.03	0.43 $\pm$ 0.04	0.026 (6.3%)	0.011
TTP ratio, mean $\pm$ SD	0.068 $\pm$ 0.027	0.096 $\pm$ 0.052	0.027 (41%)	0.032

422 Abbreviations: SD – standard deviation; BMI – Body mass index; CAT – Chronic obstructive  
423 pulmonary disease assessment test; mMRC – Modified Medical Research Council dyspnea scale;  
424 6MWT – 6 Minute walk test; TTP – time-to-peak. In CAT and mMRC, a high number means more  
425 dyspnea. In Frändin-Grimby, a lower number means less physical activity.

426

427 **Figure 1**




428

429 Abbreviations: DCE-MRI – dynamic contrast-enhanced magnetic resonance imaging

430

431 **Figure 2**



432

433

434 *Post-processing pipeline of the perfusion series*

435 a. Coronal slices from the DCE-perfusion series with the same anatomical position and window  
436 setting; from left to right: before contrast arrival, pulmonary artery-peak, parenchymal phase, aortic  
437 peak.


438 b. Pictorial explanation of normalized TTP map creation. ROI:s (red circles) were placed in the  
439 pulmonary artery and aorta. Relative enhancement was plotted against time to find the respective  
440 enhancement peak. The lung pixel TTPs time curve was then normalized to the timing of the TTP  
441 peaks in the pulmonary artery (0) and aorta (1).

442 c. Sample coronal slice of lung masked TTP map for healthy control (left) and post-COVID  
443 participant (right). The colors represent normalized TTP values (PA/0 as blue, aorta/1 as red).

444 d. Calculation of summarizing parameters. Note: numbers and the exaggerated pixel size are for  
445 illustrations purposes and do not mirror the actual data.

446

447 **Figure 3**



448


449 *Perfusion distribution curves*

450 a. Individual TTP distribution curves, Y-normalized by its intensity peak. Mean curve for each  
451 group in thick dotted lines.

452 b. TTP ratio of the respective group, representing the area-under-curve portion after the aortic  
453 peak

454 c. Mean TTP of the respective group.

455 **Figure 4**



456

457 *Sex differences in perfusion metrics*

458 a. Individual TTP distribution curves for the post-COVID males and females, respectively, Y-  
 459 normalized by its intensity peak. Mean curve for each group in thick dotted lines.


460 b. TTP ratio of the respective group, representing the area-under-curve portion after the aortic  
 461 peak

462 c. Mean TTP of the respective group.

463



464 **Figure 5**




465

466 *Scatter plots for perfusion values and clinical assessments*

467 Abbreviations: TTP – Time-To-Peak, CAT - Chronic obstructive pulmonary disease assessment  
468 test, mMRC – Modified Medical Research Council dyspnea scale. In CAT and mMRC, a high  
469 number means more dyspnea. In Frändin-Grimby, a lower number means less physical activity

470

471 **Figure 6**



472

473 *Repeatability in one healthy control*

474 a. TTP distribution curves from 2 consecutive days (mean coefficient of variation 3.7%)

475 b. TTP ratios were 0.0248 and 0.0238 for the respective scans (4.0% difference)

476 c. Mean TTPs were 0.393 and 0.382 for the respective exam (2.8% difference)